Abstract

   Background: Cholestasis is a common pathological process in a variety
   of liver diseases that may lead to liver fibrosis, cirrhosis, and even
   liver failure. Cholestasis relief has been regarded as a principal
   target in the management of multiple chronic cholestasis liver diseases
   like primary sclerosing cholangitis (PSC) and primary biliary
   cholangitis (PBC) at present. However, complicated pathogenesis and
   limited acknowledgments fettered therapeutic development. Therefore,